Bristol-Myers Squibb (NYSE:BMY) Shares Sold by FineMark National Bank & Trust

FineMark National Bank & Trust cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMYGet Rating) by 42.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,565 shares of the biopharmaceutical company’s stock after selling 47,427 shares during the quarter. FineMark National Bank & Trust’s holdings in Bristol-Myers Squibb were worth $4,088,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd raised its holdings in shares of Bristol-Myers Squibb by 185.2% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 24,513 shares of the biopharmaceutical company’s stock valued at $1,450,000 after purchasing an additional 15,919 shares in the last quarter. Stonebridge Capital Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 4.8% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 144,196 shares of the biopharmaceutical company’s stock valued at $8,532,000 after purchasing an additional 6,651 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Bristol-Myers Squibb by 215.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 197,512 shares of the biopharmaceutical company’s stock valued at $11,687,000 after purchasing an additional 134,815 shares in the last quarter. Brandywine Global Investment Management LLC raised its holdings in shares of Bristol-Myers Squibb by 20.1% in the 3rd quarter. Brandywine Global Investment Management LLC now owns 698,785 shares of the biopharmaceutical company’s stock valued at $41,347,000 after purchasing an additional 117,132 shares in the last quarter. Finally, Independence Bank of Kentucky raised its holdings in shares of Bristol-Myers Squibb by 15.1% in the 4th quarter. Independence Bank of Kentucky now owns 18,439 shares of the biopharmaceutical company’s stock valued at $1,150,000 after purchasing an additional 2,425 shares in the last quarter. Institutional investors and hedge funds own 73.07% of the company’s stock.

BMY has been the topic of several research analyst reports. Barclays lifted their price target on shares of Bristol-Myers Squibb from $66.00 to $68.00 in a research note on Monday, May 2nd. StockNews.com initiated coverage on shares of Bristol-Myers Squibb in a report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Morgan Stanley lowered their target price on shares of Bristol-Myers Squibb from $66.00 to $64.00 and set an “underweight” rating on the stock in a report on Wednesday, April 6th. Truist Financial boosted their price objective on shares of Bristol-Myers Squibb from $76.00 to $81.00 in a report on Monday, May 2nd. Finally, Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $65.00 to $70.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Buy” and a consensus price target of $71.89.

In other news, CEO Giovanni Caforio sold 30,000 shares of the firm’s stock in a transaction on Thursday, February 24th. The shares were sold at an average price of $67.00, for a total value of $2,010,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Rupert Vessey sold 74,559 shares of the firm’s stock in a transaction on Wednesday, March 16th. The shares were sold at an average price of $69.25, for a total transaction of $5,163,210.75. The disclosure for this sale can be found here. In the last three months, insiders sold 165,668 shares of company stock worth $11,459,888. Insiders own 0.09% of the company’s stock.

Shares of NYSE:BMY traded up $0.85 during trading on Monday, reaching $77.04. The stock had a trading volume of 129,658 shares, compared to its average volume of 14,897,639. Bristol-Myers Squibb has a fifty-two week low of $53.22 and a fifty-two week high of $78.46. The business has a fifty day moving average price of $74.99 and a 200-day moving average price of $67.13. The stock has a market cap of $164.02 billion, a P/E ratio of 27.02, a PEG ratio of 1.61 and a beta of 0.49. The company has a quick ratio of 1.23, a current ratio of 1.32 and a debt-to-equity ratio of 1.18.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last released its earnings results on Friday, April 29th. The biopharmaceutical company reported $1.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.92 by $0.04. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The firm had revenue of $11.65 billion during the quarter, compared to the consensus estimate of $11.34 billion. During the same period in the previous year, the firm earned $1.74 earnings per share. Bristol-Myers Squibb’s revenue was up 5.2% compared to the same quarter last year. As a group, equities analysts forecast that Bristol-Myers Squibb will post 7.57 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, May 2nd. Stockholders of record on Friday, April 1st were paid a $0.54 dividend. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.80%. The ex-dividend date was Thursday, March 31st. Bristol-Myers Squibb’s dividend payout ratio is presently 76.60%.

About Bristol-Myers Squibb (Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Read More

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.